NEWS April 17, 2017

BLOG: Cytovia, A Specialty Immuno-Oncology Pharmaceutical Company: From Vision Toward Implementation

Many IMNP shareholders have been asking about our vision and implementation plan for Cytovia. We now have a clear strategic business plan, validated by a leading consulting firm and by industry experts, to create a global specialty immuno-oncology pharmaceutical company around our core asset Ceplene.  As the plan is implemented, Cytovia would focus on commercialization […]

Keep Reading

March 27, 2017

What’s Next for Immune Pharma? Pure-Play Spin-Off Companies

Immune Pharma long term shareholders recognize the disconnect between the intrinsic value of each the key assets of the company and the stock price/ market valuation. The company first identified the potential to structure subsidiaries around asset groups: Immuno-Inflammation, Immuno-Oncology and Pain. After considering shared services from a parent company to the subsidiary, it appears that the […]

Keep Reading

February 8, 2017

CYTOVIA: Building a Leading Immuno-Oncology Company

CYTOVIA: Building a leading immuno-oncology company Immune Pharmaceuticals (NASDAQ: IMNP) recently announced the formation of Cytovia Oncology, a wholly-owned subsidiary, to leverage its immuno-oncology pipeline and unlock value with the company’s core cancer immunotherapy assets. Ceplene Moving Into Pivotal U.S. Phase 3 Ceplene is approved for use in Europe as a combination therapy with interleukin-2 […]

Keep Reading

January 3, 2017

Strategic Focus and Partnerships: Part 1

  Part 1: Focus on Bertilimumab and The Eotaxin Franchise Immune Pharma has assembled a rich pipeline with multiple opportunities to create value. After some initial financial challenges, Immune Pharma has a clean capitalization table and is ready to re-organize the company in several strategically focused entities, each independently financed and managed. These entities include […]

Keep Reading

December 6, 2016

Focus on Acute Myeloid Leukemia at the American Society of Hematology

The Immune Pharma team traveled this weekend to the annual meeting of the American Society of Hematology (ASH) in San Diego. This was an opportunity to learn about the latest developments in Acute Myeloid Leukemia(AML) and to hold a Scientific Advisory Board for our AML drug, Ceplene®. Acute Myeloid Leukemia (AML) is the most frequent […]

Keep Reading

December 1, 2016

Financing Immune Pharmaceuticals

Like many micro-cap companies, Immune Pharmaceuticals (NASDAQ:IMNP) has had to overcome the challenges of structured financings. Stock price and liquidity are key drivers for an early stage biotech company to raise sufficient capital to advance its pipeline. The good news is that IMNP finally has a clean cap table with no outstanding preferred shares, low […]

Keep Reading

November 28, 2016

Why The Bertilimumab Bullous Pemphigoid Trial is So Important

Bullous Pemphigoid (BP) is an auto-immune blistering disease of the skin which affects 30,000 Americans and an estimated 90,000 people worldwide (1/3 with moderate to severe disease). Most of the patients are over 60 years old, require several visits before being diagnosed, and have limited therapeutic alternatives. The mainstay of treatment is oral prednisone at […]

Keep Reading